BIIB Price / Book | BIOGEN INC.

BIOGEN INC. (BIIB) Price / Book

2026-09-03: Price/Book Ratio 1.78.
2026-03-31: Price/Book Ratio 1.44.
2025-12-31: Price/Book Ratio 1.42.
2025-09-30: Price/Book Ratio 1.13.

Historical market capitalization divided by filed shareholder equity.

Available history: 2008-12-31 to 2026-09-03
Data captured: 2026-09-04

Historical Price/Book Ratio

Date	Price/Book Ratio
2026-09-03	1.78
2026-03-31	1.44
2025-12-31	1.42
2025-09-30	1.13
2025-06-30	1.04
2025-03-31	1.18
2024-12-31	1.33
2024-09-30	1.73
2024-06-30	2.12
2024-03-31	2.06
2023-12-31	2.53
2023-09-30	2.57
2023-06-30	2.85
2023-03-31	2.91
2022-12-31	2.98
2022-09-30	3.03
2022-06-30	2.52
2022-03-31	2.75
2021-12-31	3.24
2021-09-30	4.04
2021-06-30	4.85
2021-03-31	3.99
2020-12-31	3.49
2020-09-30	4.17
2020-06-30	3.86
2020-03-31	4.39
2019-12-31	3.87
2019-09-30	3.07
2019-06-30	3.5
2019-03-31	3.36
2018-12-31	4.55
2018-09-30	5.17
2018-06-30	4.99
2018-03-31	4.12
2017-12-31	5.34
2017-09-30	5.15
2017-06-30	4.97
2017-03-31	5.14
2016-12-31	5.04
2016-09-30	5.66
2016-06-30	4.65
2016-03-31	5.51
2015-12-31	7.14
2015-09-30	6.49
2015-06-30	7.56
2015-03-31	8.49
2014-12-31	7.37
2014-09-30	7.49
2014-06-30	7.82
2014-03-31	7.91
2013-12-31	7.66
2013-09-30	7.04
2013-06-30	6.46
2013-03-31	6.2
2012-12-31	4.97
2012-09-30	5.3
2012-06-30	5.52
2012-03-31	4.77
2011-12-31	4.15
2011-09-30	3.63
2011-06-30	4.32
2011-03-31	3.16
2010-12-31	2.99
2010-09-30	2.7
2010-06-30	2.45
2010-03-31	2.62
2009-12-31	0
2009-09-30	2.22
2008-12-31	2.36

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Revolution Medicines, Inc. (RVMD)	United States	$42.805B	-22.69
EXELIXIS, INC. (EXEL)	United States	$14.358B	16.15
NEUROCRINE BIOSCIENCES INC (NBIX)	United States	$14.131B	24.25
HALOZYME THERAPEUTICS, INC. (HALO)	United States	$13.083B	21.59
Twist Bioscience Corp (TWST)	United States	$11.540B	-47.21
BIO-TECHNE Corp (TECH)	United States	$11.379B	74.68
REPLIGEN CORP (RGEN)	United States	$10.755B	185.31
Krystal Biotech, Inc. (KRYS)	United States	$10.210B	45.56
Kymera Therapeutics, Inc. (KYMR)	United States	$9.631B	-31.69
ImmunityBio, Inc. (IBRX)	United States	$9.157B	-9.29